ライフサイエンスコーパス: anticoagulant drug

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 atural product that is used clinically as an anticoagulant drug.

2 Heparin is a commonly used anticoagulant drug.

3 287 692 patients exposed to 230 090 years of anticoagulant drugs.

4 g, may occur following the administration of anticoagulant drugs.

5 f acute MI, and prior use of antiplatelet or anticoagulant drugs.

6 ng, and should facilitate development of new anticoagulant drugs.

7 were interviewed for use of antiplatelet or anticoagulant drugs.

8 d in the development of new antiplatelet and anticoagulant drugs.

9 ; P = 0.002), and the use of antiplatelet or anticoagulant drugs (33.9% of cases and 17.7% of control

10 Associations between use of antiplatelet or anticoagulant drugs and hemorrhage were evaluated among

11 comparable medical resource consumption (eg, anticoagulant drugs and SFJ ligation); subsequent deep-v

12 drugs, 52% (1,647/3,194) were not prescribed anticoagulant drugs, and 25% (1,740/7,008) were not pres

13 28 had lipid-lowering drugs indicated, 3,194 anticoagulant drugs, and 7,008 antihypertensive drugs.

14 Obesity alters the pharmacokinetics of some anticoagulant drugs, and IBD patients present the added

15 Several novel oral anticoagulant drugs are in development.

16 Warfarin, an important anticoagulant drug, can exist in solution in 40 distinct

17 cade and represents an attractive target for anticoagulant drug development.

18 Seminal articles describing new anticoagulant drugs for stroke prevention in atrial fibr

19 is a good target for the development of new anticoagulant drugs for the treatment of thrombotic dise

20 g platform of selective, actively reversible anticoagulant drugs for use among patients with thrombot

21 Non-vitamin K antagonist oral anticoagulant drugs have recently expanded therapeutic o

22 contamination of the widely used lifesaving anticoagulant drug heparin in 2007 has drawn renewed att

23 es deliver an increased concentration of the anticoagulant drug hirulog to the plaque compared with u

24 itoring the blood levels of this blockbuster anticoagulant drug in specific clinical situations.

25 w provides practical guidance for the use of anticoagulant drugs in patients presenting with SVT, inc

26 ainties about risks, benefits, and dosing of anticoagulant drugs in this patient population.

27 08 participants (52.2%) used antiplatelet or anticoagulant drugs, including 514 participants (44.1%)

28 In both approaches, the use of anticoagulant drugs is recommended.

29 vailability of non-vitamin K antagonist oral anticoagulant drugs may lead to better prevention of str

30 olic stroke of undetermined source, and oral anticoagulant drugs may prove to reduce stroke risk from

31 ological prevention with low, fixed doses of anticoagulant drugs, prophylaxis remains underused in pa

32 Bivalirudin is a synthetic anticoagulant drug sometimes employed as a substitute fo

33 Heparin is a commonly used anticoagulant drug that inhibits the activities of facto

34 of aspirin and the availability of new oral anticoagulant drugs that overcome the inherent drawbacks

35 Pretreatment of mice with the anticoagulant drug warfarin to block blood factor-depend

36 al trials, it is likely that additional oral anticoagulant drugs will be clinically available for str

37 duronic acid being an essential component of anticoagulant drugs with diastereoselectivity superior t

38 However, the majority of patients receive anticoagulant drugs, with heterogeneous timing of initia

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。